Ignite Creation Date:
2025-12-25 @ 5:01 AM
Ignite Modification Date:
2026-03-03 @ 2:03 AM
Study NCT ID:
NCT04032418
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-18
First Post:
2019-07-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-13
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-03-14
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-18
First Submit QC Date:
None
Study First Post Date:
2019-07-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-17
Last Update Post Date:
2025-03-18
Last Update Post Date Type:
ACTUAL